Sarepta Therapeutics, Inc. (SRPT)
USD 120.25
(-4.38%)
USD 120.25
(-4.38%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.24 Billion | 933.01 Million | 701.88 Million | 540.09 Million | 380.83 Million | 301.03 Million |
| Cost of Revenue | 150.34 Million | 139.98 Million | 97.04 Million | 63.38 Million | 56.58 Million | 34.19 Million |
| Gross Profit | 1.09 Billion | 793.02 Million | 604.83 Million | 476.71 Million | 324.24 Million | 266.84 Million |
| Operating Expenses | 1.36 Billion | 1.32 Billion | 1.05 Billion | 1.04 Billion | 846.57 Million | 610.46 Million |
| Selling, General and Administrative Expenses | 481.87 Million | 451.42 Million | 282.66 Million | 317.87 Million | 284.81 Million | 207.76 Million |
| Research and Development Expenses | 877.38 Million | 877.09 Million | 771.18 Million | 722.34 Million | 560.9 Million | 401.84 Million |
| Other Expenses | 1.55 Million | 714 Thousand | 706 Thousand | 662 Thousand | 849 Thousand | -656 Thousand |
| Cost and Expenses | 1.51 Billion | 1.46 Billion | 1.15 Billion | 1.1 Billion | 903.15 Million | 644.66 Million |
| Operating Income | -267.82 Million | -536.2 Million | -449.71 Million | -564.16 Million | -522.32 Million | -343.62 Million |
| Interest Expense | 22.01 Million | 53.24 Million | 63.52 Million | 59.94 Million | 30.66 Million | 33.7 Million |
| Income Tax Expense | 15.87 Million | 13.52 Million | -168 Thousand | 1.06 Million | 1.19 Million | -692 Thousand |
| Earnings before Tax | -520.09 Million | -689.96 Million | -418.94 Million | -553.06 Million | -713.88 Million | -362.61 Million |
| Net Income | -535.97 Million | -703.48 Million | -418.78 Million | -554.12 Million | -715.07 Million | -361.91 Million |
| Earnings Per Share Basic | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | -5.46 |
| Earnings Per Share Diluted | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | -5.46 |
| Weighted Average Shares Outstanding | 92.39 Million | 87.55 Million | 81.26 Million | 77.95 Million | 73.61 Million | 66.25 Million |
| Weighted Average Shares Outstanding (Diluted) | 92.39 Million | 87.55 Million | 81.26 Million | 77.95 Million | 73.61 Million | 66.25 Million |
| Gross Margin | 0.88 | 0.85 | 0.86 | 0.88 | 0.85 | 0.89 |
| EBIT Margin | -0.35 | -0.51 | -0.59 | -0.98 | -1.23 | -1.14 |
| Profit Margin | -0.43 | -0.75 | -0.60 | -1.03 | -1.88 | -1.20 |
| EBITDA | -439.19 Million | -582.11 Million | -306.08 Million | -453.37 Million | -652.66 Million | -316.65 Million |
| Earnings Before Tax Margin | -0.22 | -0.57 | -0.64 | -1.04 | -1.37 | -1.14 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 362.93 Million | 413.46 Million | 1.24 Billion | 396.78 Million | 331.81 Million | 261.23 Million |
| Cost of Revenue | 53.26 Million | 50.55 Million | 150.34 Million | 44.17 Million | 37.02 Million | 34.12 Million |
| Gross Profit | 309.66 Million | 362.9 Million | 1.09 Billion | 352.6 Million | 294.79 Million | 227.11 Million |
| Operating Expenses | 310.36 Million | 328 Million | 1.36 Billion | 327.98 Million | 315.63 Million | 360.63 Million |
| Selling, General and Administrative Expenses | 136.66 Million | 127 Million | - | 131.7 Million | 120.89 Million | 118.56 Million |
| Research and Development Expenses | 173.7 Million | 194.35 Million | - | 195.51 Million | 194.3 Million | 241.89 Million |
| Other Expenses | 268 Thousand | 194.35 Million | 1.55 Million | 763 Thousand | -425 Thousand | 154 Thousand |
| Cost and Expenses | 363.63 Million | 378.55 Million | 1.51 Billion | 372.15 Million | 352.65 Million | 394.75 Million |
| Operating Income | -701 Thousand | 34.9 Million | -267.82 Million | 24.62 Million | -20.84 Million | -133.51 Million |
| Interest Expense | 4.83 Million | 4.16 Million | 22.01 Million | -16.77 Million | 5.22 Million | 5.22 Million |
| Income Tax Expense | 7.11 Million | 5.32 Million | 15.87 Million | -5.28 Million | 7.76 Million | 9.35 Million |
| Earnings before Tax | 13.57 Million | 41.44 Million | -520.09 Million | 40.37 Million | -33.17 Million | -14.58 Million |
| Net Income | 6.46 Million | 36.11 Million | -535.97 Million | 45.65 Million | -40.93 Million | -23.94 Million |
| Earnings Per Share Basic | 0.07 | 0.38 | - | 0.49 | -0.46 | -0.27 |
| Earnings Per Share Diluted | 0.07 | 0.37 | - | 0.43 | -0.46 | -0.27 |
| Weighted Average Shares Outstanding | 94.61 Million | 93.99 Million | 92.39 Million | 93.61 Million | 88.88 Million | 88.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 94.61 Million | 99.11 Million | 92.39 Million | 105.59 Million | 88.88 Million | 88.74 Million |
| Gross Margin | 0.85 | 0.88 | 0.88 | 0.89 | 0.89 | 0.87 |
| EBIT Margin | 0.03 | 0.16 | - | -0.07 | 0.04 | -0.39 |
| Profit Margin | 0.02 | 0.09 | -0.43 | 0.12 | -0.12 | -0.09 |
| EBITDA | 12.03 Million | 64.45 Million | - | -28.46 Million | 12.48 Million | -101.36 Million |
| Earnings Before Tax Margin | -0.00 | 0.08 | -0.22 | 0.06 | -0.06 | -0.51 |
BGS
ARYC
BAKK
6908
GGDVY
002301